13 results
Diabetes Medications Summary Table
Insulin
Lifestyle modifications
Metformin
Sulfonylureas
GLP-1 receptor agonists - ↓ major adverse CV events
TZDs
DPP-4 inhibitors
SGLT2 inhibitors -
Diabetes Medications ... Summary Table Insulin ... Improved outcomes in CKD ... comparison #management #endocrinology ... #dm2
The “twin cycles” of diabetes, first introduced by Roy Taylor in 2008.  
#fatty liver #fatty
twin cycles” of diabetes ... fatty pancreas #diabetes ... #t2d #dm2 #insulin ... pathophysiology #endocrinology
Estimating the Total Daily Dose (TDD) of Insulin: Weight-Based Dosing
TDD in units of insulin = N
(stage IV or V CKD ... including most 2 diabetics ... Weight #Based #pharmacology ... #endocrinology ... #diabetes #DM2
Sulfonylureas - Pharmacology Summary
Mechanisms of Action: Binds to the ATP-sensitive potassium channel in pancreatic beta cells,
Sulfonylureas - Pharmacology ... cells, triggering insulin ... contraindicated in CKD ... #Summary #DM2 # ... diabetes #endocrinology
Metformin Pharmacology Summary
Mechanisms of Action:
 • Suppresses gluconeogenesis by the liver
 • Increases insulin-mediated glucose utilization
Metformin Pharmacology ... • Increases insulin-mediated ... #Metformin #Pharmacology ... #Summary #DM2 # ... diabetes #endocrinology
SGLT2 Inhibitors - Pharmacology Summary
Mechanisms of Action: Inhibits SGLT2 (sodium/glucose cotransporter 2) in the proximal tubule,
SGLT2 Inhibitors - Pharmacology ... patients with T2D ... mL/minute/1.73 m2 ... #Summary #DM2 # ... diabetes #endocrinology
Diabetes Mellitus Type 2 Inpatient Medication Guide

Classes: Biguanide, Sulfonylurea, TZD, DPP-4 inhibitor, GLP-1 receptor agonist, SGLT2i,
Diabetes Mellitus ... Sulfonylurea, TZD ... #Mellitus #DM2 ... #Medications #pharmacology ... comparison #table #endocrinology
Oral Hypoglycemics in Diabetes Management
1  INSULIN SENSITIZER
 • TZD 
     -
Hypoglycemics in Diabetes ... Management 1 INSULIN ... SENSITIZER • TZD ... #Management #pharmacology ... #DM2 #DMII #Classification
Management of Diabetes Mellitus in Patients With CKD

1. Monitor for changes in BP, serum creatinine, &
patients with T2D ... ml/min per 1.73 m2 ... evidence-based pharmacologic ... #Diabetes #CKD # ... #KDIGO #eGFR #Insulin
GLP-1 Receptor Agonists - Pharmacology Summary
Mechanisms of Action: Stimulate glucose-dependent insulin release from the pancreas (GLP-1
Receptor Agonists - Pharmacology ... glucose-dependent insulin ... patients with T2D ... #Summary #DM2 # ... diabetes #endocrinology